Fullhope Biomedical Co., Ltd

As of June 30, 2026, Fullhope Biomedical Co., Ltd carries a market capitalization of 1.15B, placing it among publicly traded companies globally. Its enterprise value stands at 851.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Fullhope Biomedical Co., Ltd has 39.91M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Fullhope Biomedical Co., Ltd maintains a current ratio of 23.59, meaning it holds 23.6x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Fullhope Biomedical Co., Ltd's stock has declined approximately 17.43% over the past 52 weeks. The 50-day moving average sits at 31.18, while the 200-day moving average is 29.17.

As of June 30, 2026, Fullhope Biomedical Co., Ltd holds 305.46M in cash and equivalents against 5.34M in total debt, resulting in a net debt position of -9.12M. Total book value stands at 538.17M, with working capital of 304.65M providing operational flexibility.